Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Receives Consensus Recommendation of “Buy” from Analysts

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLAGet Rating) has been given a consensus recommendation of “Buy” by the nine brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $18.14.

A number of equities analysts have recently weighed in on AYLA shares. Zacks Investment Research cut Ayala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 1st. Oppenheimer lowered their price target on Ayala Pharmaceuticals from $25.00 to $16.00 and set an “outperform” rating for the company in a report on Wednesday, March 30th. Maxim Group lowered their price target on Ayala Pharmaceuticals from $22.00 to $12.00 in a report on Wednesday, March 30th. Finally, Raymond James lowered their target price on Ayala Pharmaceuticals from $24.00 to $6.00 and set an “outperform” rating for the company in a report on Wednesday, March 30th.

Several institutional investors and hedge funds have recently made changes to their positions in the company. DLD Asset Management LP boosted its stake in shares of Ayala Pharmaceuticals by 9.2% in the 1st quarter. DLD Asset Management LP now owns 172,867 shares of the company’s stock valued at $688,000 after buying an additional 14,635 shares during the period. Marshall Wace LLP purchased a new position in shares of Ayala Pharmaceuticals in the 4th quarter valued at about $420,000. CSS LLC IL acquired a new stake in shares of Ayala Pharmaceuticals during the 4th quarter worth about $131,000. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Ayala Pharmaceuticals by 406,248.7% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,153,648 shares of the company’s stock worth $18,328,000 after acquiring an additional 2,153,118 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Ayala Pharmaceuticals by 36.5% during the 3rd quarter. Wellington Management Group LLP now owns 961,609 shares of the company’s stock worth $10,905,000 after acquiring an additional 257,246 shares in the last quarter. Institutional investors and hedge funds own 56.07% of the company’s stock.

NASDAQ AYLA opened at $2.10 on Friday. The business has a fifty day moving average price of $3.18 and a 200 day moving average price of $5.92. Ayala Pharmaceuticals has a one year low of $1.75 and a one year high of $14.95. The company has a market cap of $29.59 million, a P/E ratio of -0.76 and a beta of 1.39.

Ayala Pharmaceuticals (NASDAQ:AYLAGet Rating) last issued its earnings results on Monday, March 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.05). Ayala Pharmaceuticals had a negative return on equity of 115.40% and a negative net margin of 1,403.90%. On average, research analysts predict that Ayala Pharmaceuticals will post -2.55 EPS for the current fiscal year.

About Ayala Pharmaceuticals (Get Rating)

Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.

See Also

Analyst Recommendations for Ayala Pharmaceuticals (NASDAQ:AYLA)

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.